FLXS
Flexsteel Stock Falls 18% in the Session After Its Fiscal First-Quarter Results
Gross margin fell to 22.0%, operating income dropped, and cash fell to $4.4 million, while the company guided to 1% to 4% sales growth next quarter.
News
ZURA
Zura Bio Stock Jumps 19.9% on Third-Quarter Results and Trial Timing Update
The company reported a wider third-quarter net loss and said its TibuSHIELD data remains on track for the fourth quarter of 2026.
MFIC
MidCap Financial Stock Jumps 22.7% After Agreeing to Ares Capital Acquisition
MFIC holders would receive $10.88 per share in cash and Ares Capital stock, a 30.1% premium to the prior close.
HRI
Herc Holdings Stock Jumps 23% After Record Third-Quarter Results and Raised 2026 Guidance
The equipment rental company raised its full-year 2026 revenue, adjusted EBITDA and capex guidance for the second time this year, citing mega-project demand.
CLW
Clearwater Paper Stock Sinks 29% as Results and Augusta Mill Disruption Weigh
The company's Q3 2026 results included a Q4 Adjusted EBITDA outlook of $10 to 20 million, with operational problems at the Augusta mill continuing into October.
ARTV
Artiva Stock Plunges 31% After Halting AlloNK Development and Cutting 94% of Staff
The biotech is also exploring strategic alternatives, including a possible merger, sale or liquidation, after two patient deaths and weaker durability data.
RRC
Range Resources Stock Jumps 17.7% on Agreement to Be Acquired by EQT in All-Stock Deal
Range holders would receive 0.987 EQT shares for each Range share, with Range stockholders owning about 27% of the combined company.
ORKA
Oruka Stock Jumps 12.7% on Positive Week 16 Psoriasis Trial Data for ORKA-001
The 61% PASI 100 response in the high-dose group matched results from the earlier EVERLAST-A trial, and the company plans Phase 3 trials in the first half of 2027.
CLYM
Climb Bio Stock Falls 13.5% on the Day It Reported Early Kidney Drug Data
The filing, accepted before the open Monday, reported initial Phase 2 results for budoprutug in primary membranous nephropathy, and no source ties the decline to a specific item in it.
AVBP
ArriVent Shares Fall 27% on Monday, the Day Early ARR-217 Trial Data Were Filed
Neither the filing nor the press release attached to it says why the stock dropped, though the company called the early response rates encouraging.